Major medical societies released updated guidelines on Oct. 21 regarding multivessel PCI and thrombus aspiration in patients with STEMI undergoing primary PCI.

The FDA approved patiromer (Veltassa) to treat patients with hyperkalemia, which typically occurs in patients with heart failure or kidney disease.

The American Heart Association (AHA) updated its guidelines for CPR and emergency cardiovascular care on Oct. 15 with an emphasis on training bystanders and healthcare providers and using mobile technology to alert dispatchers after noticing someone is suffering from cardiac arrest.

Interventional cardiologists who received certification from the American Board of Internal Medicine (ABIM) did not have better outcomes after PCI with regards to the risks of bleeding and vascular complications compared with those who were not certified.

Since taking over as Medtronic’s CEO, Omar Ishrak has focused on three goals: improving innovation, expanding into emerging markets and becoming a leader in value-based health care, according to a Barron’s article. A Jefferies analyst called Medtronic’s acquisition of Covidien earlier this year a “bold move” and said “Ishrak changed the ethos of the company.”

A long-term follow-up of patients who underwent cardiac surgery in Sweden found there was no association between red blood cell storage times and estimated mortality at 30 days, two years and 10 years.

All adults should be screened for high blood pressure, according to a U.S. Preventive Services Task Force (USPSTF) recommendation released on Oct. 13. If adults are diagnosed with hypertension, they should confirm the measurement outside of a clinical setting with ambulatory blood pressure monitoring before starting treatment

The FDA approved idarucizumab on Oct. 16 for patients who need to reverse the blood-thinning effects of dabigatran. Boehringer Ingelheim manufactures and markets idarucizumab and dabigatran.

The FDA approved the Sapien XT transcatheter heart valve on Oct. 15 for aortic valve-in-valve procedures.

Patients at high risk for bleeding who underwent PCI had better outcomes if they received a polymer-free umirolimus-coated stent compared with a bare-metal stent, according to a randomized, double blind trial.

After two years of follow up, patients with peripheral artery disease who received a drug-coated balloon had significantly higher primary patency and a significantly lower rate of clinically driven target lesion revascularization compared with patients who received conventional percutaneous transluminal angioplasty (PTA).

The lead author of a recent trial that led to an FDA notification of potential issues with bioprosthetic aortic valves reiterated that the findings related to neurologic events were preliminary and inconclusive.